On a Friday in April 2021, as the Philippines moved deeper into another wave of COVID-19 infections, the Department of Health drew a line around the price of a single remdesivir vial, setting it between P1,500 and P8,200 for 100 milligrams. Such moments recur in every crisis: when a scarce remedy meets a frightened public, the question of fairness arrives alongside the question of supply. The department's answer was to warn that anyone who manipulated prices would face administrative and criminal consequences, and to invite citizens to report what they saw.
DOH Warns Against Overpricing of Remdesivir as Philippines Battles COVID-19 Surge
A price range for a drug many families were already worrying about
Mark
So what exactly did the DOH announce on Friday?
Mimi
A price range. A 100-milligram vial of remdesivir should cost between P1,500 and P8,200, and sellers who manipulate prices face administrative and criminal penalties.
Mark
Why issue this now?
Mimi
Infections are surging, attributed to new variants, more mobility and relaxed adherence to health protocols. Supply of remdesivir and tocilizumab had only been replenished last month after a shortfall.
Luke
Is there evidence anyone is actually overcharging?
Mimi
The report doesn't say. It describes a warning, not an enforcement action.
Mark
What about access? Is it just a matter of price?
Mimi
No. The drug is investigational, so a compassionate use permit from the Food and Drug Administration is required.
Luke
The range is wide, though. P8,200 is more than five times P1,500.
Mimi
True, and the report doesn't explain how the range was set or why it spans that much.
Mark
How would someone act on this?
Mimi
By emailing a complaint to the address the DOH gave. Beyond that, we don't yet know how complaints will be handled or how many arrive.
Luke
So the penalties are stated, but nothing is confirmed about enforcement yet.
Mimi
Right. That's the thing to watch.
Le Pouls
- A surge in COVID-19 cases is filling hospitals and pushing families toward a drug many of them barely understand.
- The DOH has set a P1,500 to P8,200 price band per 100-mg vial, and warned that overpricing could bring both administrative and criminal penalties.
- Remdesivir remains investigational, so each patient needs a compassionate use permit from the FDA before receiving it.
- Supply was only restocked last month after a shortfall, leaving the market still fragile as demand climbs.
- Public complaints sent to a dedicated DOH address will decide whether enforcement follows, and no overcharging case has yet been named.
On a Friday in April 2021, as the Philippines moved deeper into another wave of COVID-19 infections, the Department of Health drew a line around the price of a single remdesivir vial, setting it between P1,500 and P8,200 for 100 milligrams. Such moments recur in every crisis: when a scarce remedy meets a frightened public, the question of fairness arrives alongside the question of supply. The department's answer was to warn that anyone who manipulated prices would face administrative and criminal consequences, and to invite citizens to report what they saw.
On Friday, the Philippine Department of Health gave a number to a worry many families already carried: what a vial of remdesivir should cost. A 100-milligram vial, it said, must sell for between P1,500 and P8,200.
The warning was aimed at anyone tempted to charge more. Under a joint administrative order signed with other government agencies, price manipulation would draw both administrative and criminal penalties. The timing sharpened the message. The country was in the middle of a COVID-19 surge, driven by new variants, rising mobility and looser adherence to health protocols, and demand for treatments tends to climb with each wave, as hospitals fill.
Remdesivir is not an ordinary prescription. The department described it as investigational, meaning a patient needs a compassionate use permit from the Food and Drug Administration before receiving it. That permit is an extra step between the patient and the medicine, on top of the price.
The department also asked the public to report overpricing by email, the mechanism through which any penalties could begin. The warning came just after a shortage, since supplies of remdesivir and tocilizumab had been replenished only the month before.
The report does not say that any seller has been caught, nor how many complaints have arrived. What it establishes is the price band, the penalties, the permit rule and the reporting channel. What remains to be seen is whether complaints come in, and whether the department acts on them while infections keep rising.
On Friday, the Philippine Department of Health put a number on something many families were already worrying about: what a vial of remdesivir should cost. A 100-milligram vial, the department said, must be priced between P1,500 and P8,200.
The warning is aimed at anyone who might charge more. The department pointed to a joint administrative order signed with other government agencies. Under it, anyone found to have committed an illegal act of price manipulation would be penalized both administratively and criminally.
The timing matters. The Philippines is in the middle of a surge in COVID-19 infections. Health authorities have attributed it to three things: new coronavirus variants, increased mobility among the public, and a loosening of adherence to health protocols. Demand for drugs used on COVID-19 patients tends to rise with each wave of cases, and the warning reads as an attempt to head off price gouging as hospitals fill.
Remdesivir is not an ordinary prescription. The department described it as an investigational drug, and said that using it requires a compassionate use permit from the Food and Drug Administration. The permit requirement adds a regulatory step between a patient and the medicine, on top of whatever the vial costs.
The department also invited the public to report overpricing. It advised people to send complaints about overpriced remdesivir to a dedicated email address, which the published report gives in obfuscated form. Complaints sent there are the mechanism by which any penalties could begin.
The warning follows a recent shortage. The country's supply of remdesivir and of tocilizumab, another drug used on COVID-19 cases, was replenished last month after a shortfall. Supply had been tight, and it was restocked only weeks before the department set its price ceiling and floor.
The report does not say that any seller has been caught overcharging, nor does it say how many complaints have been filed so far. What it establishes is the price range, the legal consequences, the permit requirement and the channel for complaints. What to watch next is whether reports come in and whether the department acts on them while infections keep climbing.
Citations marquantes
Those found to have committed any illegal act of price manipulation would be penalized administratively and criminally.— Department of Health, citing a joint administrative order
Envie de l'histoire complète ?
Lire l'original sur manilastandard.net ↗
Health & Medicine